61364-37-2

Basic information

• Product Name: (R)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
• Synonyms: (R)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine;(-)-(R)-Mirtazapine;(14bR)-1,2,3,4,10,14bβ-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine;(R)-6-Azamianserin;(R)-Mirtazapine;R-(-)-Mirtazapine;(R)-2-methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine
• CAS NO: 61364-37-2
• Molecular Formula: C17H19N3
• Molecular Weight: 265.35286
• EINECS: 262-735-5
• Mol File: 61364-37-2.mol
• Article Data: 39

Chemical Properties

• Boiling Point: 432.4°C at 760 mmHg
• Flash Point: 215.3°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 1.11E-07mmHg at 25°C
• Refractive Index: 1.667
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (R)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine(61364-37-2)
• EPA Substance Registry System: (R)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine(61364-37-2)

Safety Data

• Hazardous Substances Data: 61364-37-2(Hazardous Substances Data)

Usage

Description

(R)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, also known as R-Mirtazapine, is an enantiomer of Mirtazapine (M365000), which is an antidepressant. R-Mirtazapine has demonstrated antinociceptive effects in acute thermal nociception, making it a potential candidate for pharmaceutical applications.

Uses

Used in Pharmaceutical Industry:
R-Mirtazapine is used as an enantiomer of Mirtazapine for its antinociceptive effects in acute thermal nociception. This application is significant because it has the potential to provide relief from pain without the pronociceptive effects observed in the S-Mirtazapine enantiomer.
Additionally, R-Mirtazapine could be further investigated for its potential use in the development of new antidepressant medications, as it is an enantiomer of an existing antidepressant with demonstrated antinociceptive properties. This could lead to the creation of more effective and safer treatments for depression and related conditions.

InChI:InChI=1/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3/t16-/m0/s1

Upstream product

• 1071838-96-4 rac-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepin-10-ol 
• 191546-96-0 3,4,10,14b-tetrahydro-2-methyl-pyrazino[2,1-a]pyrido[2,3-c][2]benzazepin-1(2H)-one 
• 1071504-86-3 (10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepin-10-ylmethyl)(2-chloro-ethyl)-methylamine 
• 1071546-33-2 (14bS)-1,3,4,14b-tetrahydro-2-methyl-pyrazino[2,1-a]pyrido[2,3-c][2]benzazepin-10(2H)-one 
• 1071546-36-5 (14bS)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepin-10-ol 
• 824954-89-4 2-[(2S)-4-methyl-2-phenyl-1-piperazinyl]-3-pyridinemethanol 
• 85650-52-8 Mirtazapine 
• 130277-16-6 2-amino-3-benzylpyridine 
• 1071504-90-9 ((R)-10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepin-10-ylmethyl)-(2-hydroxyethyl)-methylamine 
• 1071504-78-3 (R)-(-)-10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepine-10-N-methylcarboxamide 
• 1071504-65-8 10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepine-10-N-methylcarboxamide 
• 1071504-88-5 ((R)-10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepin-10-ylmethyl)-methyl-amine 
• 1071504-64-7 (10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepin-10-ylmethyl)-methyl-amine 
• 1071504-75-0 10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepine-10-carboxylic acid ethyl ester 

Downstream Products

• 61337-67-5 (-)-Mirtazapine 
• 680993-85-5 S-mirtazapine malonate 
• 61337-86-8 1,2,3,4,10,14b-hexahydro-8-bromo-2-methyl-pyrazino<2,1-a>pyrido<2,3-c><2>benzazepine 

Relevant articles and documents

Preparation method and intermediate product of mirtazapine

The invention discloses a preparation method and an intermediate product of mirtazapine. The preparation method comprises the following steps: in an organic solvent, carrying out a cyclization reaction on a compound represented by a formula I and/or an inorganic acid salt thereof in the presence of a sulfonic acid resin, and separating to obtain a solid, ie., the mirtazapine intermediate product;and carrying out an ion exchange reaction on the mirtazapine intermediate product and an alkali to obtain mirtazapine. The preparation method has the advantages of simplicity and convenience in operation, easiness in product separation, small pollution, suitability for industrial production and the like.

Simultaneous enantioselective determination of seven psychoactive drugs enantiomers in multi-specie animal tissues with chiral liquid chromatography coupled with tandem mass spectrometry

In stock farming, illegal use of antipsychotics has caused the food safety problem. This paper presents for the first time, a multi-residues method for the simultaneous enantioselective determination of seven antipsychotics in pork, beef and lamb muscles. The behaviors of Chiralpak AGP toward changes in pH and organic modifier in mobile phase were studied, and all analytes were rapidly separated within 30 min. The calibration curves of all enantiomers were linear in the range of 1–250 ng g?1, with correlation coefficient above 0.9931. The recoveries of the targeted compounds were higher than 82.1%, with repeatability and intermediate precision lower than 18.2% and 17.4%, respectively. In three matrices, the limit of detection and limit of quantification ranged from 0.20 to 0.65 ng g?1 and from 0.40 to 1.00 ng g?1, respectively. The proposed method can be used to provide additional information for the reliable risk assessment of chiral antipsychotics.

MANUFACTURING METHOD OF PYRIDINEMETHANOL COMPOUND AND MANUFACTURING METHOD OF MIRTAZAPINE

PROBLEM TO BE SOLVED: To provide a method capable of manufacturing a manufacturing intermediate of mirtazapine which is useful as an antidepressant at high yield and manufacturing high purity mirtazapine. SOLUTION: In a method for reacting 2-(4-methyl-2-phenyl-1-piperazinyl)-3-pyridinecarboxylic acid and hydrogenated bis(2-methoxyethoxy)aluminum sodium, manufacturing yield of 2-(4-methyl-2-phenyl-1-piperazinyl)-3-pyridine methanol is improved by washing a reaction mixture with alkali metal halide. Also in the method, by-production amount of dimer impurities during reaction can be suppressed and high quality mirtazapine can be manufactured in a method for reaction 2-(4-methyl-2-phenyl-1-piperazinyl)-3-pyridine methanol and sulfuric acid. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT